Source comparison
Purity Standards and Why They Matter More Than PT-141 vs Bremelanotide Labels
The single most critical variable in peptide efficacy isn't whether the supplier calls it PT-141 or bremelanotide—it's synthesis quality and purity verification. Research-grade peptides synthesised via solid-phase peptide synthesis (SPPS) should achieve ≥98% p
This comparison does not assign a generated winner or score.
- The single most critical variable in peptide efficacy isn't whether the supplier calls it PT-141 or bremelanotide—it's synthesis quality and purity verification. Research-grade peptides synthesised via solid-phase peptide synthesis (SPPS) should achieve ≥98% purity by HPLC (high-performance liquid chromatography), with remaining mass composed of truncated sequences, deletion peptides, and residual coupling reagents. A 95% pure batch contains 5% impurities—potentially including incorrect peptide fragments, residual protecting groups, or acetylation errors—that reduce receptor binding efficacy and introduce variables into experimental protocols. Mass spectrometry confirmation ensures the molecular weight matches the target (1025.18 g/mol for bremelanotide), while HPLC traces verify sequence integrity and absence of aggregation. Lyophilised peptides stored at −20°C maintain stability for 24–36 months; once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 day
- Chemical Identity
- Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
- Identical peptide sequence—no structural difference
- Molecular Weight
- 1025.18 g/mol
- Same molecular weight confirms same compound
- Mechanism of Action
- MC4R/MC3R agonist in CNS
- Identical receptor binding profile and downstream signalling
- Typical Purity Range
- 95–99% (varies by supplier)
- Purity depends on synthesis facility, not nomenclature
- Regulatory Status
- Research-use designation
- FDA-approved INN (Vyleesi brand)
- Bremelanotide is the official regulatory name post-2006
- Bottom Line
- Legacy research label still widely used
- Formal pharmaceutical name for clinical and regulatory contexts
- Choose based on purity verification and supplier reputation—not which name is used